Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
SpaceX stated that the Tesla merger requires Elon Musk's approval.

SpaceX stated that the Tesla merger requires Elon Musk's approval.

路透社路透社2026/10/22 20:56
Show original

- SpaceX (SPCX.O) revealed on Thursday that a potential merger with Tesla (TSLA.O) would require approval from controlling investor Elon Musk. Days earlier, the world’s richest man had stated he could not participate in discussions held by the special committee.

Musk said on Tuesday that a merger between his two companies, SpaceX and Tesla, would be a “good idea” and stated that both sides had established a special committee to discuss the deal.


(To facilitate non-native English speakers, Reuters has automatically translated its reports into several other languages. Since automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of automated translation. It is provided solely for the convenience of readers. Reuters accepts no responsibility for any harm or losses incurred as a result of using the automatic translation feature.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Moderna plunges by as much as 26%, setting a record for the biggest single-day drop! Melanoma vaccine data leaked early, results fall short of expectations

Clinical trial data from phase 3 of the personalized melanoma vaccine jointly developed by Moderna and Merck was unexpectedly leaked ahead of schedule. The data showed a 42% reduction in cancer recurrence risk and a 38% reduction in risk of distant metastasis. These results fell short of market expectations, as an earlier study had shown the combination therapy could reduce recurrence risk by 49% and distant metastasis risk by 59%. Moderna's stock price plunged as much as 26% intraday, later rebounded partially, and ultimately closed down 17.6%.

华尔街见闻•2026/10/22 21:01